Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Mortality at maximal · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease severity as measured by patient‐reported symptom score (total nasal symptom score) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Significant adverse event: epistaxis · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids probably leads to higher significant adverse event: epistaxis compared with placebo (moderate certainty).
1 finding from 1 review
Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · adults and children > 12 with non‐allergic rhinitis
It is very uncertain whether intranasal corticosteroids changes objective measurement of airflow: peak flow rate (expiratory) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids showed no clear difference in other adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 1 month (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 3 to 4 months (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids showed no clear difference in death in hospital; children compared with no such treatment (moderate certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids probably leads to lower need for mechanical ventilation at 1 month compared with no such treatment (moderate certainty).
1 finding from 1 review
Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low